January 15th 2024
Experts in multiple myeloma discuss highlights from the ASH 2023 meeting around transplant-eligible NDMM with particular focus on the PERSEUS and GRIFFIN trials and the clinical implications of the results of these studies.
December 19th 2023
Saad Usmani, MD, MBA, FACP, discusses the updates of XPO1 inhibitors in relapsed/refractory multiple myeloma patients.
December 14th 2023
A panel of experts discuss the evolving landscape of newly diagnosed multiple myeloma.